Significant sirolimus and dronedarone interaction in a kidney transplant recipient

Annals of Pharmacotherapy

Volumn 44, Issue 7-8, 2010, Pages 1338-1341

  Tichy, Eric M ^a   Medwid, Andrew J ^b   Mills, Elizabeth A ^c   Formica, Richard N ^d,e   Kulkarni, Sanjay ^d,e  

^a YALE NEW HAVEN HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c DUQUESNE UNIVERSITY   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Yale New Haven Transplantation Center   (United States)

Author keywords

Dronedarone; Drug interaction; Sirolimus; Transplant

Indexed keywords

AMIODARONE; DRONEDARONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; ANTIARRHYTHMIC AGENT; IMMUNOSUPPRESSIVE AGENT;

AGED; AMYLOIDOSIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG METABOLISM; DRUG WITHDRAWAL; GRAFT RECIPIENT; GRAFT REJECTION; HEART ATRIUM FIBRILLATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS DIARRHEA; KIDNEY TRANSPLANTATION; LUNG TOXICITY; MAINTENANCE THERAPY; MALE; NOROVIRUS; PRIORITY JOURNAL; THROMBOCYTOPENIA; ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; COMPLICATION; DOSE RESPONSE; DRUG INTERACTION; DRUG MONITORING; PROCEDURES;

AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; SIROLIMUS;

EID: 77954600916     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P114     Document Type: Article

References (11)

1. Package insert. Rapamune (sirolimus). Philadelphia, PA: Wyeth Laboratories, 2004. Printed 25 Jan 2010 at Yale-New Haven Hospital, New Haven, CT.
2. Package insert. Multaq (dronedarone). Bridgewater, NJ: Sanofi-Aventis U.S. LLC, 2009. Printed 25 Jan 2010 at Yale-New Haven Hospital, New Haven, CT.
3. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000;38:41-57. DOI 10.2165/00003088-200038010-00003 (Pubitemid 30055093)
4. Nalli N, Stewart-Teixeira L, Dipchand AI. Amiodarone-sirolimus/tacrolimus interaction in a pediatric heart transplant patient. Pediatr Transplant 2006;10:736-9. DOI 10.1111/j.1399-3046.2006.00561.x
5. Package insert. Cordarone (amiodarone). Philadelphia, PA: Wyeth Laboratories, 2009. Printed 26 Jan 2010 at Yale-New Haven Hospital, New Haven, CT.
6. Piccini JP, Hasselblad V, Peterson ED, et al. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol 2009;54:1089-95. DOI 10.1016/j.jacc.2009. 04.085
7. Chatelain P, Meysmans L, Matteazzi JR, et al. Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the f3-adrenoceptor and adenylate cyclase in rat heart. Br J Pharmacol 1995;116:1949-56.
8. Katoh M, Nakajima M, Yamazaki H, et al. Inhibitory effects of CYP3A4 substrates and their metabolites on p-glycoprotein-mediated transport. Eur J Pharm Sci 2001;12:505-13. DOI 10.1016/S0928-0987%2800%2900215-3
9. Zimmerman JJ. Exposure-response relationships and drug interactions of sirolimus. AAPS J 2004;6(4):1-12. DOI 10.1208/aapsj060428
10. Sadaba B, Campanero MA, Quetglas EG, et al. Clinical relevance of sirolimus drug interactions in transplant patients. Transplant Proc 2004;36:3226-8. DOI 10.1016/j.transproceed.2004.10.056
11. Horn JR, Hansten PD, Chan L-N. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007;41:674-80. DOI 10.1345/aph.1H423